Asia Pacific Malaria Treatment Market

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2030

Analysis - by Treatment (Generic Drugs, Originators, Vaccines, and Others), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)


No. of Pages: 88    |    Report Code: TIPRE00025037    |    Category: Life Sciences

Asia Pacific Malaria Treatment Market
Buy Now

The Asia Pacific malaria treatment market was valued at US$ 631.37 million in 2022 and is expected to reach US$ 5,179.15 million by 2030; it is estimated to grow at a CAGR of 30.1% from 2022 to 2030. 

Growing Strategic Initiatives by Market Players Fuel Asia Pacific Malaria Treatment Market

A few major players operating in the malaria treatment market are increasingly focusing on the adoption of various strategies such as product innovations, launches, and approvals; R&D investments; and mergers and acquisitions in order to remain competitive. A few of these initiatives are mentioned below:

In 2023, The R21/Matrix-M malaria vaccine is included in the WHO's list of prequalified vaccines. Following the recommendations of the Malaria Policy Advisory Group and the WHO Strategic Advisory Group of Experts (SAGE) on Immunization, the WHO recommended its introduction in October 2023 to prevent malaria in children. Prequalification is a requirement for UNICEF to purchase vaccinations and for Gavi, the Vaccine Alliance, to provide financial support for their deployment, which means that more children will have access to vaccines as a crucial tool in the fight against malaria.

In March 2022, tafenoquine, a novel drug used to treat a specific strain of malaria, was licensed in Australia by Medicines for Malaria Venture (MMV), which codeveloped the drug with GlaxoSmithKline (GSK) for children and adolescents. The drug is combined with the widely used antimalarial drug-chloroquine. 

In December 2021, Zydus Cadila announced the plan to develop its antimalarial drug ZY19489 with Medicines for Malaria Venture, which received US FDA approval. According to the company, the Phase I trial of ZY19489 demonstrated a long half-life and the potential for a single-dose cure for malaria. In a separate malaria challenge trial, strong antimalarial activity was displayed after a single oral dose of ZY19489.

In January 2021, GSK, PATH, and Bharat Biotech (BBIL) declared that a product transfer agreement was signed for the malaria vaccine RTS,S/AS01E. The agreement included transferring the manufacturing of the RTS,S antigen portion of the vaccine and granting a license for all rights related to the malaria vaccine to BBIL. GSK retains production of the vaccine adjuvant (AS01E) and supplies it to BBIL.

Therefore, the abovementioned strategic initiatives by the market players are expected to provide growth opportunities for the malaria treatment market in the coming years.

Asia Pacific Malaria Treatment Market Overview

Malaysia, Indonesia, New Zealand, Vietnam, the Philippines, Singapore, and Thailand are among the major countries in the Rest of Asia Pacific. Most of these are low- and middle-income countries, with high healthcare expenditures. According to the National Centre for Infectious Diseases 2022 report, ~100-300 malaria cases (80% vivax) per annum are imported in Singapore. A joint secretariat headquartered in the regional hub of Singapore facilitates a cross-border collaboration between APLMA and Asia Pacific Malaria Elimination Network (APMEN) to eliminate malaria from Asia Pacific with tailored solutions. 

The Global Health Group report states that nearly one-third (32%) of total malaria cases in Malaysia occur in Peninsula Malaysia, and the majority of these are found in the Central, Southeastern, and northern coastal regions. For example, young working males are at high risk of getting infected with malaria, and nearly 50% of Malaysians diagnosed with malaria reportedly work in agriculture and other outdoor jobs. The program includes 100% confirmatory testing of suspected malaria cases, mandatory reporting of detected cases, integrated vector management, and string community participation, with a cadre of volunteer primary healthcare workers selected and trained in malaria diagnosis and treatment. Further, Malaysia is a country partner of the APMEN, a network composed of 18 Asia Pacific countries and other stakeholders working to eliminate malaria in the country. 

Thus, the abovementioned factors will foster the growth of the malaria treatment market in this region.

Asia Pacific Malaria Treatment Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Malaria Treatment Market Revenue and Forecast to 2030 (US$ Million)
Get more information on this report

Asia Pacific Malaria Treatment Strategic Insights

Strategic insights for the Asia Pacific Malaria Treatment provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

strategic-framework/asia-pacific-malaria-treatment-market-strategic-framework.webp
Get more information on this report

Asia Pacific Malaria Treatment Report Scope

Report Attribute Details
Market size in 2022 US$ 631.37 Million
Market Size by 2030 US$ 5,179.15 Million
Global CAGR (2022 - 2030) 30.1%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By Treatment
  • Generic Drugs
  • Originators
  • Vaccines
By Route of Administration
  • Oral
  • Parenteral
By Distribution Channel
  • Direct Tender
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Regions and Countries Covered Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
Market leaders and key company profiles
  • Cipla Ltd
  • Sun Pharmaceutical Industries Ltd
  • Sanofi SA
  • GSK Plc
  • Novartis AG
  • Pfizer Inc
  • AdvaCare Pharma USA LLC
  • Lupin Ltd
  • Get more information on this report

    Asia Pacific Malaria Treatment Regional Insights

    The geographic scope of the Asia Pacific Malaria Treatment refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

    geography/asia-pacific-malaria-treatment-market-geography.webp
    Get more information on this report

    Asia Pacific Malaria Treatment Market Segmentation 

    The Asia Pacific malaria treatment market is segmented based on treatment, route of administration, distribution channel, and country. Based on treatment, the Asia Pacific malaria treatment market is segmented into generic drugs, originators, vaccines, and others. The vaccines segment held the largest market share in 2022. 

    In terms of route of administration, the Asia Pacific malaria treatment market is bifurcated into oral and parenteral. The oral segment held a larger market share in 2022. 

    By distribution channel, the Asia Pacific malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held the largest market share in 2022. 

    Based on country, the Asia Pacific malaria treatment market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. The Rest of Asia Pacific dominated the Asia Pacific malaria treatment market share in 2022. 

    Cipla Ltd, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis AG, Pfizer Inc, AdvaCare Pharma USA LLC, and Lupin Ltd are some of the leading players operating in the Asia Pacific malaria treatment market. 

    The List of Companies - Asia Pacific Malaria Treatment Market

    1. Cipla Ltd
    2. Sun Pharmaceutical Industries Ltd
    3. Sanofi SA
    4. GSK Plc
    5. Novartis AG
    6. Pfizer Inc
    7. AdvaCare Pharma USA LLC
    8. Lupin Ltd

    Frequently Asked Questions
    How big is the Asia Pacific Malaria Treatment Market?

    The Asia Pacific Malaria Treatment Market is valued at US$ 631.37 Million in 2022, it is projected to reach US$ 5,179.15 Million by 2030.

    What is the CAGR for Asia Pacific Malaria Treatment Market by (2022 - 2030)?

    As per our report Asia Pacific Malaria Treatment Market, the market size is valued at US$ 631.37 Million in 2022, projecting it to reach US$ 5,179.15 Million by 2030. This translates to a CAGR of approximately 30.1% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Malaria Treatment Market report typically cover these key segments-

    • Treatment (Generic Drugs, Originators, Vaccines)
    • Route of Administration (Oral, Parenteral)
    • Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

    What is the historic period, base year, and forecast period taken for Asia Pacific Malaria Treatment Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Malaria Treatment Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2030
  • Who are the major players in Asia Pacific Malaria Treatment Market?

    The Asia Pacific Malaria Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Cipla Ltd
  • Sun Pharmaceutical Industries Ltd
  • Sanofi SA
  • GSK Plc
  • Novartis AG
  • Pfizer Inc
  • AdvaCare Pharma USA LLC
  • Lupin Ltd
  • Who should buy this report?

    The Asia Pacific Malaria Treatment Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Malaria Treatment Market value chain can benefit from the information contained in a comprehensive market report.

    Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now